Stephen K. Brannan - Feb 1, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol: KRTX
Transactions as of: Feb 1, 2022
Transactions value $: -$780,659
Form type: 4
Date filed: 2/2/2022, 03:10 PM
Previous filing: Jan 3, 2022
Next filing: Feb 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$13.6K	+2.5K	+33.33%	$5.45^*	10K	Feb 1, 2022	Direct
transaction	KRTX	Common Stock	Options Exercise	$56.2K	+7.73K	+77.28%	$7.27^*	17.7K	Feb 1, 2022	Direct
transaction	KRTX	Common Stock	Sale	-$850K	-7.73K	-43.59%	$110.05	10K	Feb 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-2.5K	-5.72%	$0.00	41.2K	Feb 1, 2022	Common Stock	2.5K	$5.45	Direct	F2
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-7.73K	-19.18%	$0.00	32.6K	Feb 1, 2022	Common Stock	7.73K	$7.27	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3	This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.